{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T20:10:08Z","timestamp":1723925408561},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ymgmr.2024.101109","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T02:55:32Z","timestamp":1719370532000},"page":"101109","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-na\u00efve patients with late-onset Pompe disease: A pooled analysis of clinical trials"],"prefix":"10.1016","volume":"40","author":[{"given":"Tahseen","family":"Mozaffar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Riou Fran\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Msihid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pragya","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Proskorovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Periquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"An Haack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Pollissard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2024.101109_bb0005","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgmr.2024.101109_bb0010","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non-classic Pompe\u2019s disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): an update on clinical aspects","volume":"7","author":"Toscano","year":"2019","journal-title":"Ann. Transl. Med."},{"year":"2006","series-title":"Myozyme. Summary of Product Characteristics","author":"European Medicines Agency","key":"10.1016\/j.ymgmr.2024.101109_bb0020"},{"year":"2010","series-title":"LUMIZYME. Highlights of Prescribing Information","author":"U.S. Food & Drug Administration","key":"10.1016\/j.ymgmr.2024.101109_bb0025"},{"key":"10.1016\/j.ymgmr.2024.101109_bb0030","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0035","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/gim.2018.2","article-title":"Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study","volume":"20","author":"Hahn","year":"2018","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/biom10091339","article-title":"Pompe disease: new developments in an old lysosomal storage disorder","volume":"10","author":"Meena","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymgmr.2024.101109_bb0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0050","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"year":"2021","series-title":"NEXVIAZYMETM Highlights of Prescribing Information","author":"Sanofi","key":"10.1016\/j.ymgmr.2024.101109_bb0055"},{"year":"2022","series-title":"Nexviadyme Summary of Product Characteristics","author":"Sanofi","key":"10.1016\/j.ymgmr.2024.101109_bb0060"},{"key":"10.1016\/j.ymgmr.2024.101109_bb0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0070","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1212\/WNL.0000000000200746","article-title":"Long-term safety and efficacy of Avalglucosidase alfa in patients with late-onset Pompe disease","volume":"99","author":"Dimachkie","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2024.101109_bb0075","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.107077","article-title":"Nonparametric analysis of forced vital capacity in the COMET trial demonstrates superiority of avalglucosidase alfa vs alglucosidase alfa","volume":"138","author":"Diaz-Manera","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0085","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF02294361","article-title":"Model selection and Akaike\u2019s information criterion (AIC): the general theory and its analytical extensions","volume":"52","author":"Bozdogan","year":"1987","journal-title":"Psychometrika"},{"key":"10.1016\/j.ymgmr.2024.101109_bb0095","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2307\/1913828","article-title":"Information criteria for discriminating among alternative regression models","volume":"46","author":"Sawa","year":"1978","journal-title":"Econometrica"},{"key":"10.1016\/j.ymgmr.2024.101109_bb0100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nmd.2015.11.009","article-title":"Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease","volume":"26","author":"Johnson","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0105","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13023-020-01469-7","article-title":"Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study","volume":"15","author":"Yuan","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0110","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0115","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1007\/s00415-020-09936-8","article-title":"Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start","volume":"267","author":"Stockton","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0120","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0125","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","article-title":"STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa","volume":"268","author":"Gutschmidt","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0130","first-page":"S154","article-title":"Efficacy and safety of avalglucosidase alfa in participants with late-onset Pompe disease after 145 weeks\u2019 treatment during the COMET trial (LBP.01)","volume":"32","author":"Schoser","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgmr.2024.101109_bb0135","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/cts.13619","article-title":"Artificial intelligence in rare disease diagnosis and treatment","volume":"16","author":"Wojtara","year":"2023","journal-title":"Clin. Transl. Sci."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426924000624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426924000624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T19:35:25Z","timestamp":1723923325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426924000624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":27,"alternative-id":["S2214426924000624"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101109","relation":{},"ISSN":["2214-4269"],"issn-type":[{"type":"print","value":"2214-4269"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-na\u00efve patients with late-onset Pompe disease: A pooled analysis of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101109"}}